No Data
The "Congressional stock gods" have new actions: In the past six months, they have invested 2.9 million dollars in pharmaceutical companies.
① Due to Trump's tariffs and Health Secretary Kennedy's reforms, stock prices in the American pharmaceutical Industry have been falling consistently; ② Although the stock prices of pharmaceutical companies have underperformed the market, U.S. Congress members are constantly Buying pharmaceutical company Stocks; ③ Financial disclosures show that during the first six months of the Trump administration, U.S. Representatives and Senators purchased up to $2.9 million in pharmaceutical company Stocks.
Report: The United States is pressuring Europe to make "unilateral concessions," with the best-case scenario being "to reach an agreement on principles and continue discussions."
"They either offer a good deal or they will have to pay as we say." U.S. President Trump has been escalating threats against the EU, pressuring them to make unilateral concessions, while the EU is preparing for "dual scenarios." Analysis suggests that even if an agreement is reached, many of Trump's tariffs will remain, leading to unequal arrangements. The best case scenario is to reach a consensus on principles and extend the negotiation deadline past the critical date of July 9.
Vaxart Shareholders Reject Stock Split
Press Release: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
12 Health Care Stocks Moving In Friday's Intraday Session
Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4
